Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 44 citing articles:

Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials
Alessandro Di Federico, Alessandro Rizzo, Riccardo Carloni, et al.
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 4, pp. 361-369
Closed Access | Times Cited: 82
Nanobodies in cell-mediated immunotherapy: On the road to fight cancer
Amirhosein Maali, Monireh Gholizadeh, Saba Feghhi-Najafabadi, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 31
Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial
Étienne Garin, Lambros Tselikas, Boris Guiu, et al.
Journal of Nuclear Medicine (2024) Vol. 65, Iss. 2, pp. 264-269
Open Access | Times Cited: 11
The association between tumour heterogeneity and immune evasion mechanisms in hepatocellular carcinoma and its clinical implications
Kaina Chen, Timothy Wai Ho Shuen, Pierce K. H. Chow
British Journal of Cancer (2024) Vol. 131, Iss. 3, pp. 420-429
Open Access | Times Cited: 9
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Bruno Sangro, Lorenza Rimassa, Maxime Ronot, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 8
Radioembolization plus Immune Checkpoint Inhibitor Therapy Compared with Radioembolization plus Tyrosine Kinase Inhibitor Therapy for the Treatment of Hepatocellular Carcinoma
Kirema Garcia-Reyes, Ricki A Gottlieb, K. Menon, et al.
Journal of Vascular and Interventional Radiology (2024) Vol. 35, Iss. 5, pp. 722-730.e1
Closed Access | Times Cited: 5
Peritumor tertiary lymphoid structures are associated with infiltrating neutrophils and inferior prognosis in hepatocellular carcinoma
Tianchen Zhang, Xinjun Lei, Weili Jia, et al.
Cancer Medicine (2022) Vol. 12, Iss. 3, pp. 3068-3078
Open Access | Times Cited: 26
Neoadjuvant therapies in resectable hepatocellular carcinoma: Exploring strategies to improve prognosis
Yanan Ma, Xuemei Jiang, Peipei Song, et al.
BioScience Trends (2024) Vol. 18, Iss. 1, pp. 21-41
Open Access | Times Cited: 4
Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis
Jiaxi Zheng, Minghai Shao, Weifang Yang, et al.
International Immunopharmacology (2022) Vol. 112, pp. 109244-109244
Open Access | Times Cited: 20
The current understanding of the immune landscape relative to radiotherapy across tumor types
Chrysanthi Iliadi, Laurine Verset, Christelle Bouchart, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Immunotherapies in clinical development for biliary tract cancer
Arndt Vogel, Melanie Bathon, Anna Saborowski
Expert Opinion on Investigational Drugs (2020) Vol. 30, Iss. 4, pp. 351-363
Open Access | Times Cited: 30
Combining Selective Internal Radiation Therapy with Immunotherapy in Treating Hepatocellular Carcinoma and Hepatic Colorectal Metastases: A Systematic Review
Khalil Ramdhani, Maarten L. J. Smits, Marnix G. E. H. Lam, et al.
Cancer Biotherapy and Radiopharmaceuticals (2023) Vol. 38, Iss. 4, pp. 216-224
Closed Access | Times Cited: 7
Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope
Weili Jia, Tianchen Zhang, Qianyun Yao, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 11
Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma– with Emphasis on Locoregional Therapy for Oligoprogression
Tsung‐Hao Liu, San‐Chi Chen, Kun‐Ming Rau, et al.
Liver Cancer (2024) Vol. 13, Iss. 5, pp. 509-521
Open Access | Times Cited: 1
The New Perspectives Journal of Medicine
Yanan Ma, Jianjun Gao, Fanghua Qi, et al.
Deleted Journal (2024)
Open Access | Times Cited: 1
A Novel Nomogram to Predict Prognosis of Advanced Hepatocellular Carcinoma Treated with Intensity-Modulated Radiotherapy Plus Anti-PD1
Meiling He, Chunfeng Liang, Ya-Dan Pang, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 913-925
Open Access | Times Cited: 1
Transarterial Embolization Enhances Programmed Cell Death Ligand 1 Expression and Influences CD8+T Lymphocytes Cytotoxicity in an Orthotopic Hepatocellular Carcinoma Rat Model
Shen Zhang, Lin Xu, Jia-Qing Li, et al.
CardioVascular and Interventional Radiology (2024) Vol. 47, Iss. 10, pp. 1372-1381
Closed Access | Times Cited: 1
Locoregional therapies combined with immune checkpoint inhibitors for liver metastases
Xingchen Zhang, Yuwen Zhou, Gui-Xia Wei, et al.
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
New frontiers in radioembolization
Arian Mansur, Peiman Habibollahi, Adam Fang, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 1
Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective
Gun Ha Kim, Jin Hyoung Kim, Pyeong Hwa Kim, et al.
Korean Journal of Radiology (2021) Vol. 22, Iss. 11, pp. 1822-1822
Open Access | Times Cited: 11
Expanding the role of interventional oncology for advancing precision immunotherapy of solid tumors
Yasushi Kimura, Mario Ghosn, Waseem Cheema, et al.
Molecular Therapy — Oncolytics (2021) Vol. 24, pp. 194-204
Open Access | Times Cited: 11
Advances in Diagnostic and Interventional Radiology in Hepatocellular Carcinoma
Osman Öcal, Daniel Rössler, Jens Ricke, et al.
Digestive Diseases (2021) Vol. 40, Iss. 4, pp. 458-467
Open Access | Times Cited: 10
Individualised dosimetry and safety of SIRT for intrahepatic cholangiocarcinoma
Kathy Willowson, Enid M. Eslick, Dale L. Bailey
EJNMMI Physics (2021) Vol. 8, Iss. 1
Open Access | Times Cited: 10
Immunomodulation for hepatocellular carcinoma therapy: current challenges
Zuzana Macek Jílková, Julien Ghelfi, Thomas Decaens
Current Opinion in Oncology (2021) Vol. 34, Iss. 2, pp. 155-160
Closed Access | Times Cited: 10
Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities
Leonardo Gomes da Fonseca, Raphael L. C. Araújo
World Journal of Gastroenterology (2022) Vol. 28, Iss. 28, pp. 3573-3585
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top